Inventions

Polish patent: PL 247148  

PROMOTER ACTIVATED BY MYB47 AND MYB95 PROTEINS AND AN EXPRESSION SYSTEM CONTAINING IT
(PL) PROMOTOR AKTYWOWANY PRZEZ BIAŁKA MYB47 I MYB95 ORAZ ZAWIERAJĄCY GO SYSTEM EKSPRESYJNY   

Priority date: 2021-08-06 
Inventors: Shayan Sarkar, Arpan Kumar Basak, Kenji Yamada, Jakub Bizan, Paweł Bednarek, Paweł Czerniawski 
Holder: Uniwersytet Jagielloński, Institute of Bioorganic Chemistry of the Polish Academy of Sciences

The subject of the present invention is a promoter activated by the MYB47 and MYB95 proteins and the expression system containing it, which may be employed in plant biotechnology.

Polish patent no. P 247148 protects an innovative promoter activated by the MYB47 and MYB95 proteins, together with an advanced expression system offering broad commercial potential in plant biotechnology. This gene-expression regulation technology harnesses natural MYB transcription factors, which play key roles in controlling plant physiological processes. MYB47 regulates leaf senescence via modulation of the jasmonate signaling pathway, while MYB95 functions as a mobile transcriptional activator.
Plant MYB-type promoters deliverprecise control over gene expression, yielding multiple advantages:
- enhanced production yields;
- improved stability of expression systems;
- capability for tissue-specific expression control.
The invention can be used across numerous industry sectors, including: 
- biotechnology companies – for example, production of recombinant proteins in plant bioreactors;
- pharmaceutical industry – for example, manufacture of biopharmaceuticals and vaccines;
cosmetic sector – for example, generation of raw materials rich in novel active ingredients;
- agrobiotechnology – for example, engineering of crop plants to increase yield, and resistance to pests, diseases, and herbicides.

More about the patent: 
https://ewyszukiwarka.pue.uprp.gov.pl/search/pwp-details/P.438703?lng=en

Polish patent: PL 233178 

HUMAN OVARIAN CANCER CELL CULTURE MODEL FOR PACLITAXEL-INDUCED INVERSE RESISTANCE TO PACLITAXEL AND CISPLATIN AND USE THEREOF  
(PL) MODEL KOMÓRKOWY LUDZKIEGO RAKA JAJNIKA W HODOWLI O ZAINDUKOWANEJ PAKLITAKSELEM ODWROTNEJ OPORNOŚCI NA PAKLITAKSEL I CISPLATYNĘ ORAZ ZASTOSOWANIE TEGO MODELU   

Priority date:2017-01-26 
Inventors: Jolanta Szenajch, Michał Góralski, Luiza Handschuh, Alicja Szabelska-Beręsewicz, Idzi Siatkowski, Aleksandra Świercz, Joanna Zyprych-Walczak 
Holders: Military Institute of Medicine, Institute of Bioorganic Chemistry of the Polish Academy of Sciences, Poznan University of Life Sciences  

The subject of the present invention is a method for generating a human ovarian cancer cell line with reversed resistance to paclitaxel (PTX) and cisplatin (CDDP), as well as the cell lines obtained thereby and their use for in vitro studies of anticancer drug mechanisms or therapeutic approaches. The invention introduces novel protocols for establishing cell lines and panels thereof as a model for gene expression profiling, enabling the analysis of signaling pathways using next-generation sequencing (NGS) technology. The cell lines disclosed herein may also be employed in studies of drug-resistance mechanisms and in personalized medicine.  

Polish patent no. PL 233178 protects the method for producing human ovarian cancer cell lines with reversed resistance to paclitaxel and cisplatin, based on the parental A2780 line. This technology has been successfully applied to derive a series of six ovarian cancer cell lines, which are also claimed by the patent. The derived cell lines exhibit a progressively increasing resistance to paclitaxel concomitant with a decreasing resistance to cisplatin, reflecting the most commonly observed chemoresistance profiles in clinical practice.The developed solutions have commercial potential across multiple sectors of the biomedical and pharmaceutical industry, including:
- in vitro studies of drug resistance: identification of signaling pathways (e.g., mTOR, MAPK) via next-generation sequencing;
- personalized oncology: selection of effective therapies based on tumor genetic profiles using expression biomarkers;
- pharmaceutical development platform: testing novel resistance inhibitors (e.g., ABCB1 transporter antagonists) under conditions simulating clinical relapse;
- oncology diagnostics: validation of predictive assays for taxane and platinum-derivative response.

  More about the patent: https://ewyszukiwarka.pue.uprp.gov.pl/search/pwp-details/P.420318?lng=en

Patent japoński: JP 7278323 
 
(EN)METHOD FOR CREATING PREDICTIVE MODEL FOR PREDICTING GLAUCOMA RISK IN SUBJECT, METHOD FOR DETERMINING GLAUCOMA RISK IN SUBJECT USING SUCH PREDICTIVE MODEL, DEVICE FOR PREDICTING GLAUCOMA RISK IN SUBJECT, COMPUTER PROGRAM AND COMPUTER READABLE MEDIUM
対象者の緑内障のリスクを予測する予測モデルを生成する方法、当該予測モデルを用いて対象者の緑内障リスクを決定する方法、対象者の緑内障リスクを予測する装置、コンピュータプログラム及びコンピュータ可読媒体   

Priority date: 2020-04-09 
Inventors: Robert H. Wasilewicz, Cezary Mazurek, Juliusz Pukacki, Hubert ŚwierczyńskiHolder: Institute of Bioorganic Chemistry of the Polish Academy of Sciences, Poznan Supercomputing and Networking Center, Robert Henryk Wasilewicz

PROBLEM TO BE SOLVED: To create a predictive model for predicting glaucoma risk in a subject.  

SOLUTION: A method for creating a predictive model for predicting glaucoma risk in a subject comprises a step of creating a diagnostic model of each subject comprising, for each one of a plurality of subjects: recording a 24-hour profile of eyeball parameters; dividing the recorded 24-hour profile of eyeball parameters at least into subperiods: determining, in each subperiod, features describing a single subject in the form of at least one aggregating attribute; creating a record containing the determined features describing a single subject; assigning a label indicating a diagnosis (diseased/healthy) made by a physician to the created record. Furthermore, the method includes a step of creating a predictive model, based on a set of records created for the plurality of subjects, using supervised machine learning mechanisms based on one or more algorithms.
  
The invention disclosed under Japanese patent no. JP 7278323 may contribute to the early detection of glaucoma—the world’s second leading cause of blindness. The developed method for creating predictive models combines advanced machine-learning algorithms with analysis of ocular biorhythms, enabling risk identification years before clinical symptoms appear.
 
Key elements of the technology include:
-  automated analysis of ophthalmic data using neural networks and deep-learning methods;
- a portable diagnostic device integrating measurements of intraocular pressure, corneal thickness, and blood-flow parameters;
- a SaaS platform that allows users to monitor trends in real time with disease-progression forecasting functionality.
The commercialization potential spans multiple sectors, including: 
- telemedicine – for remote patient monitoring;
- pharmaceutical industry – for monitoring therapy efficacy;
- cosmetology – for assessing the impact of products on eye health.

More about the patent: https://patentscope.wipo.int/search/en/detail.jsf?docId=JP340276234&_fid=US339098737

 US patent: US 10329566  

NUCLEIC ACID MOLECULE, EXPRESSION CASSETTE, EXPRESSION VECTOR, EUKARYOTIC HOST CELL, INDUCTION METHOD OF RNA INTERFERENCE IN EUKARYOTIC HOST AND USE OF THE NUCLEIC ACID MOLECULE IN THERAPY OF DISEASES INDUCED BY EXPANSION OF TRINUCLEOTIDE CAG REPEATS   

Priority date: 2013-09-02 
Inventors: Włodzimierz Krzyżosiak, Marta Olejniczak, Paulina Gałka-Marciniak, Agnieszka Fiszer 
Holder: Institute of Bioorganic Chemistry of the Polish Academy of Sciences   

Subjects of the invention are: nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of RNA interference in eukaryotic host and use of nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG-type repeats. Solution relates to the new concept of treating hereditary human neurological diseases caused by expansion of CAG-type trinucleotide repeats using RNA interference technology.  

US patent no. US 10329566 represents an extension of polish patent no. PL 243776, which protects an innovative technology targeting the treatment of diseases caused by pathological CAG repeat expansions – including Huntington’s disease, spinocerebellar ataxias, and spinal muscular atrophy. The developed nucleic acid molecule operates through allele-selective RNA interference (RNAi), selectively silencing mutated gene alleles without affecting their normal variants.The key element of the invention is an expression vector containing an optimized gene cassette, enabling sustained expression of therapeutic siRNA in eukaryotic cells, thus facilitating the development of therapies for diseases representing unmet clinical needs. 
The technology provides:
- precise silencing of mutated gene alleles while preserving normal allele function;
- minimization of off-target effects through bioinformatics algorithms employed in sequence design;
- scalable production in cellular systems (HEK, CHO).
This technology may be applied in: 
- advanced therapy for neurodegenerative and neuromuscular diseases;
- personalized treatment regimens based on CAG expansion analysis;
- development of orphan drugs for rare polyglutamine disorders.


 More about the patent: https://patentscope.wipo.int/search/en/detail.jsf?docId=US236453291&_fid=PL329177782

 US patent: US 9970004  

NUCLEIC ACID MOLECULE, EXPRESSION CASSETTE, EXPRESSION VECTOR, EUKARYOTIC HOST CELL, INDUCTION METHOD OF RNA INTERFERENCE IN EUKARYOTIC HOST AND USE OF NUCLEIC ACID MOLECULE IN THERAPY OF DISEASES INDUCED BY EXPANSION OF TRINUCLEOTIDE CAG REPEATS

Priority date: 2013-09-02 
Inventors: Włodzimierz Krzyżosiak, Marta Olejniczak, Paulina Gałka-Marciniak, Agnieszka Fiszer 
Holder: Institute of Bioorganic Chemistry of the Polish Academy of Sciences  

Subjects of the invention are: nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of RNA interference in eukaryotic host and use of nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG-type repeats. Solution relates to the new concept of treating hereditary human neurological diseases caused by expansion of CAG-type trinucleotide repeats using RNA interference technology. 

US patent no. US 9,970,004 describes a novel RNA-based therapy for neurodegenerative diseases—leveraging RNA interference (RNAi) technology – to target pathogenic CAG trinucleotide repeat expansions in the treatment of hereditary disorders such as Huntington’s disease, spinocerebellar ataxias, and other rare neurodegenerative conditions. 
Key components of the technology include:
- an innovative nucleic acid molecule with a duplex–loop structure;
- expression cassettes and vectors for therapeutic delivery;
- optimized eukaryotic host cell lines;
- a precise RNAi induction method.
Core features of the proposed solution are: 
- allele-selective activity – specifically targeting mutated gene variants;
- enhanced safety compared with conventional antisense oligonucleotides;
- sustained therapeutic effect via vector-mediated delivery;
- potential for application in personalized medicine.


More about the patent: https://patentscope.wipo.int/search/en/detail.jsf?docId=US189864240&_fid=US236453291

Polish patent: PL 218747  

PREPARATION WITH HIGHER PLANT FERRITIN CONTENT AND OTHER FORMS OF IRON, PROCESS FOR PREPARATION AND THE USE THEREOF
(PL) SPOSÓB WYTWARZANIA KOMPOZYCJI O PODWYŻSZONEJ ZAWARTOŚCI FERRYTYNY ROŚLINNEJ I INNYCH FORM ŻELAZA, KOMPOZYCJA I JEJ ZASTOSOWANIE DO WYTWARZANIA PREPARATU DO SUPLEMENTOWANIA DIETY CZŁOWIEKA   

Priority date: 2009-06-24 
Inventors: Magdalena Zielińska-Dawidziak, Tomasz Twardowski 
Holders: Uniwersytet Przyrodniczy w Poznaniu, Institute of Bioorganic Chemistry of the Polish Academy of Sciences   

The subject of the present invention is a method for producing a composition with an elevated content of plant ferritin and other iron forms, as well as the composition itself and its use in the manufacture of a human dietary supplement. In particular, the invention discloses a novel formulation for human dietary supplementation to prevent iron‐deficiency anemia. The invention also describes a method for preparing the composition and its application in the form of dried, milled sprouts enriched in iron—derived, for example, from leguminous, cruciferous plants or cereal grains—whose cultivation is conducted under stress conditions to stimulate biosynthesis of plant ferritin as a dietary agent for anemia prevention. This invention aligns with current nutraceutical trends and the development of functional supplements based on natural plant ingredients, offering an innovative solution to improve iron bioavailability and support health.  

The subject of the invention is protected by Polish patent no. PL 218747, which describes an iron biofortification technology for plant products. The patent details a method for producing a composition with elevated plant ferritin content—a natural, highly bioavailable form of iron. The patented technology enables the production of dietary supplements and functional foods that effectively prevent iron deficiency and anemia. Plant ferritin exhibits exceptional bioavailability compared to conventional iron forms. 
The technology disclosed in the patent may be applied across multiple industries, including:
- Pharmaceutical industry: manufacturing advanced iron preparations;
- Food industry: producing iron‐fortified functional foods;
- Cosmetic industry: developing nutraceuticals to support hair and nail health.


More about the patent: https://ewyszukiwarka.pue.uprp.gov.pl/search/pwp-details/P.388379?lng=en

European patent: EP 2225228  

METHOD OF OBTAINING OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES, AN ANTI-AGING COMPOSITION AND USE OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES IN THE MANUFACTURE OF ANTI-AGING COMPOSITION  

Priority date: 2007-11-25 
Inventors: Jan Barciszewski, Wojciech T. Markiewicz, Eliza Wyszko, Maria Markiewicz, Monika Piwecka, Katarzyna Rolle, Ewelina Adamska, Marcin K. Chmielewski 
Holder:Institute of Bioorganic Chemistry of the Polish Academy of Sciences  

The subjects of the present invention are the method of preparation of 4-furfurylcytosine and/or its derivatives, its use in the manufacture of anti-aging compositions and an anti-aging composition. As 4-furfurylcytosine and/or its derivatives possesses a series of biological properties it might be use as a composition having excellent anti-aging effect to prevent the sagging of skin and loss of luster and to improve sufficiently its aesthetic appearance without significantly change the growth rate and the total growth ability of the skin. Optimal methods of manufacturing this compound, while at the same time obtaining the highest possible process efficiency, with particular emphasis on its utility in the pharmaceutical and cosmetic industries are presented.  

European patent no. EP 2225228 protects an innovative method for producing 4-N-furfurylcytosine and its derivatives, opening new opportunities in the cosmetic and pharmaceutical industries. The active ingredient demonstrates documented anti-aging properties confirmed by studies in cellular, yeast, and mouse models.4-N-furfurylcytosine functions as a senomorphic/senolytic agent – mitigating cellular aging symptoms by improving mitochondrial function and reducing reactive oxygen species production, while also providing protection against DNA damage. Unlike traditional anti-aging ingredients, it does not eliminate senescent cells but effectively slows degenerative processes.The production technology encompasses an optimized synthesis process using cytosine, furfurylamine, and a catalyst, ensuring high yield and premium product quality.Formulations containing this innovative ingredient effectively prevent skin laxity and loss of radiance, while improving elasticity and overall appearance. 
The commercial potential may  include the applications in:
- dietary supplements;
- advanced dermocosmetics;
- anti-wrinkle creams and anti-aging serums.

More about the patent: https://ewyszukiwarka.pue.uprp.gov.pl/search/pwp-details/EP08851400?lng=en https://worldwide.espacenet.com/patent/search/family/040568369/publication/EP2225228A2?q=ap%3DEP08851400

Polish patent: PL 216370  

THE MANNER OF OBTAINING OF 4-N-FURFURYLOCITOSIN, NON-AGEING COMPOSITION AND APPLICATION OF 4-N-FURFURYLOCITOSIN FOR PRODUCTION OF NON-AGEING COMPOSITION  
(PL) SPOSÓB OTRZYMYWANIA 4-N-FURFURYLOCYTOZYNY, KOMPOZYCJA ANTYSTARZENIOWA ORAZ ZASTOSOWANIE 4-N-FURFURYLOCYTOZYNY DO WYTWARZANIA KOMPOZYCJI ANTYSTARZENIOWEJ   

Priority date: 2007-11-25 
Inventors: Jan Barciszewski, Wojciech T. Markiewicz, Eliza Wyszko, Maria Markiewicz, Monika Piwecka, Katarzyna Rolle, Ewelina Adamska, Marcin K. Chmielewski 
Holder:Institute of Bioorganic Chemistry of the Polish Academy of Sciences  

The subject of the present invention is a method for producing 4-furfurylcytosine (4-FC) and/or its derivatives, and its use in the manufacture of anti-aging compositions and an anti-aging composition. Because 4-furfurylcytosine and/or its derivatives exhibit a range of biological activities, they may be employed as anti-aging agents to prevent skin laxity and loss of radiance, as well as to improve aesthetic appearance. Optimal production methods for this compound are disclosed, achieving maximal process yield with particular emphasis on applicability in the pharmaceutical and cosmetic industries.  

Polish patent no. PL 216370 protects an optimized technology for the synthesis of 4-N-furfurylcytosine (4-FC) and its derivatives. 4-FC is a natural cytosine derivative (one of the key nucleotide components) with proven anti-aging (senomorphic/senolytic), antioxidant, and cellular repair activities. The developed synthesis method offers a high process yield (>85%), enabling scale-up for pharmaceutical, cosmetic, and biotechnological industry needs. The patent also covers the method of producing anti-aging compositions and the compositions themselves. 
This technology may be applied in:
- premium dermocosmetics (anti-aging creams and serums) containing ingredients with scientifically validated activity;
- dietary supplements that support healthy aging.  

More about the patent: https://ewyszukiwarka.pue.uprp.gov.pl/search/pwp-details/P.383867?lng=en

Polish patent application: P 452392  

AROMATIC AMIDOPHOSPHORYL COMPOUND, METHOD FOR ITS PRODUCTION, ITS USE, AND AN INTERMEDIATE COMPOUND FOR PREPARING THE AROMATIC AMIDOPHOSPHORYL COMPOUND  
(PL) AMIDOFOSFORYNOWY ZWIĄZEK AROMATYCZNY, SPOSÓB JEGO WYTWARZANIA, JEGO ZASTOSOWANIE ORAZ ZWIĄZEK POŚREDNI DO OTRZYMYWANIA AMIDOFOSFORYNOWEGO ZWIĄZKU AROMATYCZNEGO   

Priority date: 2025-06-18 
Inventors: Martyna Mateja-Pluta, Agnieszka Kiliszek 
Holder: Institute of Bioorganic Chemistry of the Polish Academy of Sciences  

The subject of the present invention is aromatic amidophosphine compounds generally suitable for use as non-nucleotide linkers. These compounds, referred to as interstrand cross-linking agents (ICLs), enable precise manipulation of DNA or RNA sequences by their site-specific incorporation during solid-phase nucleic acid synthesis. In particular, the invention relates to methods for genetic engineering of DNA or RNA, DNA recombination technologies, and modified DNA and/or RNA fragments.  

Polish patent application no. P 452392 protects innovative aromatic amidophosphine compounds that serve as non-nucleotide linkers (ICLs), allowing for the precise insertion of these linkers at any position within a nucleotide sequence during automated solid-phase synthesis. Owing to their unique molecular architecture, these compounds combine flexibility with exceptional stability, unlocking new possibilities in genetic engineering, DNA recombination technologies, and the design of functional oligonucleotides.The methodology described in the patent application facilitates effortless incorporation of an amidophosphine moiety at any desired site along the nucleic acid chain, enhancing hybridization accuracy and resistance of the nucleic acid to hydrolytic degradation.Commercial applications of this technology may include:
- design of novel RNA- and DNA-based molecules with therapeutic potential;
- development of new, highly stable molecular probes for use in molecular diagnostics.


 The application has not yet been published by the Patent Office.

Polish patent application: P 452059  

NUCLEIC ACID MOLECULE FOR SILENCING EXPRESSION OF THE TMPRSS2-ENCODING GENE, EXPRESSION CASSETTE, EXPRESSION VECTOR, PHARMACEUTICAL COMPOSITION, NUCLEIC ACID MOLECULE FOR USE IN THERAPY, NUCLEIC ACID MOLECULE FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF A TMPRSS2-DEPENDENT VIRAL DISEASE, AND IN VITRO METHOD FOR SILENCING EXPRESSION OF THE TMPRSS2-ENCODING GENE 
(PL) CZĄSTECZKA KWASU NUKLEINOWEGO DO WYCISZANIA EKSPRESJI GENU KODUJĄCEGO BIAŁKO TMPRSS-2, KASETA EKSPRESYJNA, WEKTOR EKSPRESYJNY, KOMPOZYCJA FARMACEUTYCZNA, CZĄSTECZKA KWASU NUKLEINOWEGO DO ZASTOSOWANIA W TERAPII, CZĄSTECZKA KWASU NUKLEINOWEGO DO ZASTOSOWANIA W LECZENIU I/LUB PROFILAKTYCE CHOROBY WIRUSOWEJ ZALEŻNEJ OD TMPRSS-2 ORAZ SPOSÓB IN VITRO WYCISZANIA EKSPRESJI GENU KODUJACEO BIAŁKO TMPRSS-2.   

Priority date: 2025-05-16 
Inventors: Agnieszka Belter, Marta Olejniczak, Jarosław Synak, Marta Szachniuk 
Holder: Institute of Bioorganic Chemistry of the Polish Academy of Sciences  

The present invention relates to gene-silencing using RNA interference (RNAi) reagents, specifically artificial microRNAs – also known as amiRNAs. These molecules offer superior gene-silencing specificity and reduced off-target effects compared with other RNAi tools. Their clinical success demonstrates their efficacy and safety as therapeutic agents across a broad spectrum of human diseases. Identifying host-cell factors essential for viral entry and replication defines new targets for prophylactic and therapeutic interventions against viral infections.  

Polish patent application no. P 452059 protects an innovative antiviral technology employing artificial microRNAs (amiRNAs) to precisely silence expression of the TMPRSS2 gene – a critical transmembrane protease required for SARS-CoV-2, influenza, and other respiratory viruses to enter host cells. The engineered nucleic acid molecule delivers effective therapy via RNAi-mediated blockade of viral replication. Artificial microRNAs outperform conventional RNAi methods through enhanced target specificity and markedly reduced side effects. Clinical studies of analogous approaches confirm the safety and efficacy of this therapeutic strategy for diverse human diseases. 
Key advantages of the disclosed technology include:
- precisely targeted therapy against host factors exploited by viruses for infection and replication, opening new avenues for antiviral prophylaxis and treatment; 
- host-directed therapy – targeting stable host proteins rather than rapidly mutating viral antigens to ensure durable therapeutic benefit. 
Commercial potential may encompass applications in:
- pharmaceutical and medical sectors – for the development of novel antiviral therapies;
- biotechnology industry – for leveraging existing infrastructure in the production of therapeutic nucleic acids.  

The application has not yet been published by the Patent Office.

Polish patent application: P 450139  

4-N-FURFURYLCYTOSINE AND COMPOSITION CONTAINING IT FOR MEDICAL APPLICATIONS  
(PL) 4-N-FURFURYLOCYTOZYNA I KOMPOZYCJA JĄ ZAWIERAJĄCA DO ZASTOSOWAŃ MEDYCZNYCH   

Priority date: 2024-10-25 
Inventors: Eliza Wyszko, Agnieszka Fedoruk-Wyszomirska, Paweł Pawelczak, Dorota Gurda-Woźna, Małgorzata Giel-Pietraszuk, Marta Orlicka-Płocka 
Holder: Institute of Bioorganic Chemistry of the Polish Academy of Sciences  

The present invention relates generally to 4-N-furfurylcytosine and compositions containing 4-N-furfurylcytosine for medical applications. The invention concerns 4-N-furfurylcytosine and compositions comprising it for use as a pharmaceutical agent, in particular for preventing and/or treating neurodegenerative diseases.  

The disclosed invention, protected by Polish patent application no. P 450139, covers 4-N-furfurylcytosine (4-FC)—an innovative cytosine derivative with demonstrated anti-aging and neuroprotective properties. The patent application also protects compositions containing 4-FC for medical use, including as a drug, and for the prevention and/or treatment of neurodegenerative disorders. As a low-molecular-weight bioactive compound, 4-FC offers broad commercialization potential in the pharmaceutical, cosmetic, and biotechnology sectors.Preclinical studies confirm that 4-FC exhibits potent senolytic (anti-aging) activity by reducing oxidative stress, enhancing mitochondrial function, and inhibiting cellular aging processes. This compound has shown efficacy in preclinical models for preventing neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. 
The market potential of this innovation includes:
- anti-aging therapies and regenerative medicine;
- pharmaceuticals for preventing and/or ameliorating neurodegenerative diseases;
- dietary supplements supporting healthy aging;
- premium cosmetics with proven anti-aging efficacy.


The application has not yet been published by the Patent Office.

Polish patent application: P 447752  

METHOD FOR SYNTHESIZING NUCLEIC ACIDS AND OLIGONUCLEOTIDES  
(PL) SPOSÓB SYNTEZY KWASÓW NUKLEINOWYCH ORAZ OLIGONUKLEOTYDÓW   

Priority date: 2024-02-12 
Inventors: Marcin Chmielewski, Jolanta Brzezińska, Stanisław Trzciński, Joanna StrzelecHolder: FutureSynthesis sp. z o.o., Institute of Bioorganic Chemistry of the Polish Academy of Sciences  

The subject of the invention is a method for synthesizing nucleic acids and oligonucleotides on a solid support, a matrix for solid-phase synthesis of nucleic acids and oligonucleotides, and a method for producing the matrix.  

Polish patent application no. P 447752 protects an innovative solid-phase synthesis technology for nucleic acids and oligonucleotides, which can streamline the production of RNA therapeutics and molecular diagnostics. The disclosed solution encompasses an advanced oligonucleotide synthesis matrix along with an innovative manufacturing process, offering significant advantages over conventional phosphoramidite methods. 
Distinctive features of the presented technology include:
- enhanced DNA/RNA synthesis yield for pharmaceutical applications;
- cost optimization in the production of nucleic-acid-based therapeutics;
- applicability in personalized medicine and gene therapies;
- compatibility with automated oligonucleotide synthesis platforms. 
The invention may be applied across the biotechnology sector, pharmaceutical industry, molecular diagnostics, and cosmetology. This innovation can support the development of RNA vaccines, diagnostic biomarkers, and antisense therapies.  

The application has not yet been published by the Patent Office.

International patent application under the PCT procedure: PCT/PL2023/050017
regional / national phase: EP 23722102 / P 440687  

A LOW MOLECULAR WEIGHT COMPOUND FOR USE IN THE TREATMENT OF SPINOCEREBELLAR ATAXIA TYPE 3  

Priority date: 2022-03-18 
Inventors: Maciej Figiel, Piotr Piasecki, Kalina Wiatr 
Holder: Institute of Bioorganic Chemistry of the Polish Academy of Sciences  

A subject of the application is low molecular weight compound for use in the treatment of spinocerebellar ataxia type 3, which is selected from bortezomib, carfilzomib, VLX1570, or oprozomib.  

International patent application no. PCT/PL2023/050017 protects an innovative method for treating spinocerebellar ataxia type 3 (SCA3/Machado–Joseph disease) – one of the most common inherited neurodegenerative disorders. The invention, filed under PCT/PL2023/050017 (EP 23722102), discloses a novel use of known proteasome inhibitors – bortezomib, carfilzomib, VLX1570, and oprozomib – in the therapy of this hitherto incurable disease.These compounds, already approved for oncology indications, demonstrate therapeutic potential against SCA3, a disorder characterized by progressive cerebellar atrophy and motor dysfunction. The patent application describes how proteasome inhibition may slow neurodegeneration and alleviate SCA3 symptoms. 
Potential commercial applications include:
- pharmaceutical companies seeking new indications for existing drugs (drug repurposing);
- biotechnology firms developing therapies for rare diseases.


More about the patent: https://patentscope.wipo.int/search/en/detail.jsf?docId=EP447196134&_fid=WO2023177314

European patent application: EP 22461629 
regional / national phase:P 439456  

ZERO-VALENT IRON, ESPECIALLY AGED FOR USE AS AN ANTIVIRAL AGENT, A METHOD FOR THE PREPARATION OF ZERO-VALENT IRON AND ZERO-VALENT IRON PREPARED USING THE METHOD   

Priority date: 2021-11-08 
Inventors: Elżbieta Kierzek, Klaudia Wieczorek, Zenon Foltynowicz, Karol Muc 
Holder: Institute of Bioorganic Chemistry of the Polish Academy of Sciences  

The subject of the present application is zero-valent iron for use as an antiviral agent, particularly for the prophylaxis and/or treatment of viral infections, especially those caused by viruses from the Orthomyxoviridae family, such as the influenza virus – particularly influenza A virus – as well as for use as a disinfectant. The application also encompasses a method for producing zero-valent iron. The invention disclosed under European Patent Application No. EP 22461629 describes zero-valent iron with potent antiviral properties. The subject of the invention is an innovative nanomaterial that opens new possibilities in combating viral infections, particularly the influenza A virus from the Orthomyxoviridae family.  

The invention possesses several distinctive features:
- An innovative form of zero-valent iron with enhanced biological activity;
- Broad-spectrum activity against viral pathogens;
- Application of environmentally friendly nanomaterial production technology without toxic additives.  
Key commercial applications of the described technology may include the following sectors:
- medicine: advanced medical nanotechnologies in antiviral therapy;
- pharmaceuticals and biotechnology: development of novel antiviral drugs and prophylactic preparations;
- cosmetics industry: innovative disinfectants with antiseptic properties;
- chemical industry: specialized nanomaterials for sanitary applications.  

More about the patent: https://ewyszukiwarka.pue.uprp.gov.pl/search/pwp-details/P.439456?lng=en

 Europejskie zgłoszenie patentowe: EP 22461591 
regional / national phase: P 438703  

A PROMOTOR ACTIVATED BY THE MYB47 AND MYB95 PROTEINS AND THE EXPRESSION SYSTEM CONTAINING IT  
(PL) PROMOTOR AKTYWOWANY PRZEZ  BIAŁKA MYB47 I MYB95 ORAZ ZAWIERAJĄCY GO SYSTEM EKSPRESYJNY   

Priority date: 2021-08-06 
Inventors: Shayan Sarkar, Arpan Kumar Basak, Kenji Yamada, Jakub Bizan, Paweł Bednarek, Paweł Czerniawski 
Holder: Jagiellonian University, Institute of Bioorganic Chemistry of the Polish Academy of Sciences   

Disclosed is a promoter activated by the MYB47 and MYB95 proteins and an expression system containing the same, which may be used in plant biotechnology.  

European patent application no. EP 22461591, which is based on Polish Patent Application No. P 438703, encompasses an innovative promoter activated by MYB47 and MYB95 proteins together with an advanced expression system possessing broad commercial potential in plant biotechnology.This gene expression regulation technology utilizes natural MYB transcription factors, which play pivotal roles in regulating plant physiological processes. MYB47 controls leaf senescence through modulation of the jasmonate pathway, while MYB95 functions as a mobile transcription factor.MYB-type plant promoters provide precise gene expression control, yielding multiple benefits:
- increased production efficiency;
- enhanced stability of expression systems;
- capability for tissue-specific expression control.
The invention offers broad application opportunities:biotechnology companies – for production of recombinant proteins in plant bioreactors;
pharmaceutical industry – for manufacturing biopharmaceuticals and vaccines;
cosmetics sector – for obtaining raw materials enriched with innovative active ingredients;
agrobiotechnology – for engineering crop plants to increase yields and resistance to pests, diseases, and herbicides.


More about the patent: https://patentscope.wipo.int/search/en/detail.jsf?docId=EP393713939&_fid=PL391906734